NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) – Pipeline Review, H2 2017’, provides in depth analysis on NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Infectious Disease and Respiratory under development targeting NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)

The report reviews NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics and enlists all their major and minor projects

The report assesses NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bial – Portela & Ca SA

GlaxoSmithKline Plc

Jyant Technologies Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Overview 6

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Companies Involved in Therapeutics Development 19

Bial - Portela & Ca SA 19

GlaxoSmithKline Plc 19

Jyant Technologies Inc 20

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Drug Profiles 21

(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

(leucine + metformin hydrochloride) - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

(leucine + PDE5 Inhibitor) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

BIA-6512 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

resveratrol - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

resveratrol - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

SRT-3025 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

toxoflavin - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Dormant Products 34

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Discontinued Products 36

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC

3.5.1.) - Product Development Milestones 37

Featured News & Press Releases 37

Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Association's 76th Annual Scientific Sessions 37

Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions 37

May 18, 2016: NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions 38

Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes 38

Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment 39

Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease 39

Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy 40

Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions 41

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Bial – Portela & Ca SA, H2 2017 19

Pipeline by GlaxoSmithKline Plc, H2 2017 19

Pipeline by Jyant Technologies Inc, H2 2017 20

Dormant Products, H2 2017 34

Dormant Products, H2 2017 (Contd..1), H2 2017 35

Discontinued Products, H2 2017 36

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports